Last reviewed · How we verify
Imatinib mesylate plus Gemcitabine
At a glance
| Generic name | Imatinib mesylate plus Gemcitabine |
|---|---|
| Sponsor | Gruppo Italiano MEsotelioma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (PHASE2)
- Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors (PHASE1)
- Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer (PHASE2)
- Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer (PHASE2)
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma (PHASE2)
- Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer (PHASE2)
- Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imatinib mesylate plus Gemcitabine CI brief — competitive landscape report
- Imatinib mesylate plus Gemcitabine updates RSS · CI watch RSS
- Gruppo Italiano MEsotelioma portfolio CI